2 Biotechs Raise Combined $116M After IPOs Price Low
Eye-disease treatment company Oyster Point Pharma Inc. and cancer-focused drug developer Rapt Therapeutics Inc. made their public debuts Thursday after raising a combined $116 million in initial public offerings that priced...To view the full article, register now.
Already a subscriber? Click here to view full article